SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 2nd, 2024 • PolyPid Ltd. • Surgical & medical instruments & apparatus • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 1, 2024 by and among PolyPid Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.PolyPid Ltd. • August 2nd, 2024 • Surgical & medical instruments & apparatus • New York
THIS ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [__________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (the “Initial Exercise Date”) and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on August 6, 2026 and (ii) the 10th Trading Day following the date on which the Company issues a press release announcing the recommendation by Data Safety Monitoring Board regarding its unblinded interim analysis in the Company’s SHIELD II Phase 3 trial resulting in (a) the stopping of the trial due to positive efficacy; or (b) continuation to planned final (up to 630 subjects) (the “Termination Date”) but not thereafter, to subscribe for and purchase from PolyPid Ltd., an Israeli company (the “Company”), up to [______] ordinary shares, no par value per share (the “Ordinary Share(s)”) (as subject to adjus
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 2nd, 2024 • PolyPid Ltd. • Surgical & medical instruments & apparatus
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, by and among the Company and each Purchaser (the “Purchase Agreement”).
SECOND AMENDMENT (this “Amendment”) Dated August 1, 2024 to:Security Agreement • August 2nd, 2024 • PolyPid Ltd. • Surgical & medical instruments & apparatus
that certain AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO US$15,000,000 dated as of April 5, 2022, as amended on March 29, 2023 (the “Loan Agreement”) between Kreos Capital VI (Expert Fund) LP., a partnership with limited liability incorporated in Jersey whose registered office is at 47 Esplanade, St Helier, Jersey (the “Lender” or “Kreos”, which expressions shall include its successors and assigns), and PolyPid Ltd., a company organized under the laws of the State of Israel, company no. 514105923 whose registered office is at 18 Ha’Sivim St., Petach-Tikva 4959376, Israel (the “Borrower”).
